Literature DB >> 20001666

Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases.

Debjani Ghosh1, George C Tsokos.   

Abstract

Spleen tyrosine kinase (Syk) is involved in the development and function of B and T cells, the Fc receptor-mediated degranulation of basophils and mast cells. Recent work has assigned important roles for Syk in the aberrant function of T cells in patients with systemic lupus erythematosus (SLE), osteoclasts, and urate crystal-induced neutrophil stimulation. Preclinical and early clinical studies have urged Syk inhibition for the treatment of patients with rheumatoid arthritis, whereas ex vivo experiments and preclinical studies point to a therapeutic potential of Syk inhibition in patients with SLE and crystal-induced arthritides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20001666     DOI: 10.3109/08916930903374717

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  17 in total

Review 1.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

2.  Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion.

Authors:  Omer Nuri Pamuk; Peter H Lapchak; Poonam Rani; Polly Pine; Jurandir J Dalle Lucca; George C Tsokos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-03       Impact factor: 4.052

3.  Oxidative stress and endosome recycling are complementary mechanisms reorganizing the T-cell receptor signaling complex in SLE.

Authors:  Andras Perl
Journal:  Clin Immunol       Date:  2011-12-30       Impact factor: 3.969

Review 4.  Cellular targeting in autoimmunity.

Authors:  Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

5.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

6.  c-Abl-Mediated Tyrosine Phosphorylation of PARP1 Is Crucial for Expression of Proinflammatory Genes.

Authors:  Ameer Ali Bohio; Aman Sattout; Ruoxi Wang; Ke Wang; Rajiv Kumar Sah; Xiaolan Guo; Xianlu Zeng; Yueshuang Ke; Istvan Boldogh; Xueqing Ba
Journal:  J Immunol       Date:  2019-08-09       Impact factor: 5.422

7.  Pathogenic mechanisms in systemic lupus erythematosus.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 8.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

9.  FcγR mediates TLR2- and Syk-dependent NLRP3 inflammasome activation by inactivated Francisella tularensis LVS immune complexes.

Authors:  Ellen B Duffy; Sivakumar Periasamy; Danielle Hunt; James R Drake; Jonathan A Harton
Journal:  J Leukoc Biol       Date:  2016-06-30       Impact factor: 4.962

10.  A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.

Authors:  Sook Ryun Park; Giovanna Speranza; Richard Piekarz; John J Wright; Robert J Kinders; Lihua Wang; Thomas Pfister; Jane B Trepel; Min-Jung Lee; Sylvia Alarcon; Seth M Steinberg; Jerry Collins; James H Doroshow; Shivaani Kummar
Journal:  Cancer Chemother Pharmacol       Date:  2013-02-13       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.